Cooperative Agreement 2451674
Award Date
4/15/25
Completion Date
3/31/27
Dollars Obligated
$1.3M
Federal Agency
National Science Foundation
Awardee
Biodevek Inc. (C16MAJV41YM5)
Federal Grant Program
47.084
Assistance Type
Cooperative Agreement
Place of Performance
Boston, MA 02134, USA
Similar Awards
This $962,735 cooperative agreement from the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships program (CFDA 47.084) supports the development of an enhanced biodegradable tissue adhesive for gastrointestinal surgical wound closure applications by Bezwada Biomedical LLC. The small business will refine a polyurethane-based adhesive formulation and assess its in vivo performance to identify a safe, easy-to-use lead tissue adhesive that can help prevent anastomotic...
This $999,783 Phase II Small Business Innovation Research (SBIR) cooperative agreement from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) program supports Intact Therapeutics' development of a thermogel-based drug delivery platform for the treatment of upper gastrointestinal bleeding (UGIB). Intact Therapeutics' proprietary thermogel technology aims to rapidly stop UGIB prior to endoscopic treatment, potentially reducing patient morbidity,...
Karios Technologies LLC, a for-profit organization, received a $274,954 SBIR Phase I grant from the National Science Foundation (NSF) Technology, Innovation, and Partnerships program (CFDA 47.084) to develop a novel, ready-to-use, large volume delivery system for in situ forming biomaterials. The biomaterials are intended to serve as tissue sealants, scar tissue reducers, and vehicles for drug or cell delivery during surgical procedures. The project aims to transfer a proprietary biomaterial...
This $1,000,000 Cooperative Agreement award from the National Science Foundation (NSF) under the NSF Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) supports the development of a sustained-release, biodegradable drug delivery system using anti-inflammatory nanoparticles and Hedgehog pathway antagonists. The goal is to create a localized treatment for post-traumatic injuries and complications in orthopedic surgery that can improve patient outcomes and reduce societal costs...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Cooperative Agreement award of $1,000,000 to Theromics Inc., a minority-owned small disadvantaged business, aims to develop a novel protein-based gel to improve the effectiveness and safety of thermal tumor ablation procedures. The project will involve creating a computational model to predict the thermal behavior of the gel, conducting preclinical studies to quantify temperatures, ablation zone size,...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $305,000 aims to develop a novel mammalian cell-based nano-biological coating for implantable medical devices. The key objectives are to: (1) characterize nanoparticles produced by different cells on titanium and stainless-steel orthopedic implants, (2) determine the antibacterial, anti-inflammatory, and bone/fibroblast cell growth properties of the coated surfaces, and (3)...
This $275,000 federal Project Grant awarded by the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (CFDA 47.084) program supports the development and validation of an aerogel-based wound dressing material platform with integrated fluid management, biofilm prevention, and rapid infection detection properties. The project aims to create a novel wound dressing solution that can improve the management of chronic wounds, surgical sites, and burns by mitigating...
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under CFDA Program 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research, provides $1,955,984 to Biodevek Inc. to develop GastroShield, a sprayable biocompatible adhesive biomaterial for endoscopic management of gastrointestinal (GI) lesions and prevention of GI bleeding. The project aims to achieve critical pre-clinical study milestones, including scaling up manufacturing,...
The National Science Foundation (NSF) awarded a $275,000 Small Business Innovation Research (SBIR) Phase I project grant to Agil Therapeutics Inc. under the NSF Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084). This two-year project aims to develop a novel cryoablation system for minimally invasive treatment of type 2 diabetes. The system is designed to deliver a highly controlled and targeted cryogenic agent to the duodenum, with the goal of remodeling the duodenal tissue to...
This SBIR Phase I grant award from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) is for the development of an advanced wound care product to treat diabetic foot ulcers. Therapeutic Bandage Products, Inc. will receive $305,000 to develop a patented microneedle bandage that delivers three therapeutic agents to disinfect the wound, prevent biofilm formation, and activate the immune system. This innovative product has significant...